Canaccord analyst Kyle Mikson downgraded SomaLogic to Hold from Buy with a $2.50 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SLGC:
- SomaLogic and Korea’s DNA Link partner to bring the 7,000-plex SomaScan® platform to the fast-growing Asia-Pacific proteomics market
- SomaLogic researchers identify key proteins to aid in early detection of lung, colon and breast cancer and ovarian tumors
- SomaLogic expands agreement with Novo Nordisk to 2025
- SomaLogic sees FY23 revenue 80M-$84M consensus $81.62M
- SomaLogic reports Q2 EPS (13c), consensus (16c)